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Despite its well-known histological and clinical features, Hodgkin’s lymphoma (HL) has recently been the object of intense research
activity, leading to a better understanding of its phenotype, molecular characteristics, histogenesis, and possible mechanisms
of lymphomagenesis. There is complete consensus on the B-cell derivation of the tumor in most cases, and on the relevance
of Epstein-Barr virus infection and defective cytokinesis in at least a proportion of patients. The REAL/WHO classification
recognizes a basic distinction between lymphocyte predominance HL (LP-HL) and classic HL (cHL), reflecting the diﬀerences
in clinical presentation and behavior, morphology, phenotype, and molecular features. cHL has been classified into four subtypes:
lymphocyte rich, nodular sclerosing, with mixed cellularity, and lymphocyte depleted. The borders between cHL and anaplastic
large-cell lymphoma have become sharper, whereas those between LP-HL and T-cell-rich B-cell lymphoma remain ill defined.
Treatments adjusted to the pathobiological characteristics of the tumor in at-risk patients have been proposed and are on the way
to being applied.
1. Introduction
Hodgkin’s lymphoma (HL) is a lymphoid tumor repre-
senting less than 1% of all de novo neoplasms occurring
every year world wide [1]. Its diagnosis is based on the
identification of characteristic multinucleated giant cells
within an inflammatory milieu. These cells—termed Reed-
Sternberg (RS) or diagnostic cells—represent the body of
the tumor; they measure 20–60 μm in diameter and display
a large rim of cytoplasm and at least two nuclei with
acidophilic or amphophilic nucleoli, covering more than
50% of the nuclear area (Figure 1). The tumoral population
also includes a variable number of mononuclear elements—
Hodgkin’s cells (HCs)—showing similar cytological features
to RS cells and neoplastic cell variants, each corresponding to
a specific subtype of HL.Molecular studies have only recently
shown that in most if not all cases RS cells, Hodgkin’s cells,
and cell variants belong to the same clonal population, which
is derived from peripheral B cell [1–9]. Accordingly, the
disease has been included amongmalignant lymphomas, and
the term “Hodgkin’s lymphoma” has been proposed [10–12].
However, although HRS cells are B lymphoid cells, they
are unlike any normal B cell. Furthermore, their characteris-
tics definitely contrast with a possible “stem cell” potential.
Interestingly, it was recently shown that both the L428 and
KM-H2 HL cell lines contained rare B-cell subpopulations
responsible for the generation and maintenance of the
predominant HRS cell population [13]. Intriguingly, the B
cells within the HL cell lines expressed immunoglobulin light
chain, the memory B-cell antigen CD27, and the stem cell
2 Advances in Hematology
SN II MC
LR LD
CD15 CD30
EBER CD20
Figure 1: Histopathological features of classical Hodgkin lymphoma (cHL). At morphology (H&E staining), it is possible to distinguish
nodular sclerosis (NS)∗, mixed cellularity (MC), lymphocyte rich (LR), and lymphocyte-depleted (LD) subtypes. At immunophenotyping,
cHL is typically CD15+, CD30+∗, possibly EBER+, and CD20−/+ (Olympus BX41 microscope, Olympus CAMEDIA C-7070 camera,
magnification ×400, colours balanced after acquisition with Adobe Photoshop). ∗Note the typical Reed-Sternberg cells in the insets.
marker aldehyde dehydrogenase (ALDH) [13]. Grippingly,
CD27+/ALDH++ B-cells, clonally related to lymph node HRS
cells, were also detected in the blood of HL patients. Indeed,
though the significance of such circulating clonotypic B-cells
has to be defined, the authors suggested that they may be the
initiating cells for HL [13].
Although regarded as “diagnostic,” RS cells are not exclu-
sive to HL because similar elements can be seen in reactive
lesions (such as infectious mononucleosis), B and T cell
lymphomas, carcinomas, melanomas, and sarcomas [14].
Thus, the presence of an appropriate cellular background—
along with the results of immunophenotyping—is basic
for the diagnosis. The reactive milieu, which can form
up to 99% of the total population examined, consists
of small lymphocytes, histiocytes, epithelioid histiocytes,
neutrophils, eosinophils, plasma cells, and fibroblasts in
diﬀerent proportions, depending on the histological subtype
of HL. It is sustained by an autocrine and/or paracrine
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production of several cytokines including, among others,
IL-5, IL-8, IL-9, CCL-5, and CCL-28 (see below). The
release of these molecules is also responsible for most of
the symptoms recorded in patients with HL, in addition
to the ability of the neoplastic cells to escape from growth
controls and immunosurveillance. More recently, it has been
proposed that hepatocyte growth factor and c-MET might
constitute an additional signaling pathway between RS cells
and the reactive cellular background, aﬀecting adhesion,
proliferation, and the survival of RS cells [15].
1.1. Histopathological Classification. In 1832, Sir Thomas
Hodgkin provided the first macroscopic description of the
process in a paper entitled “On some morbid appearances
of the absorbent glands and spleen.” In 1898 and 1902,
Carl Sternberg and Dorothy Reed independently described
the typical “diagnostic” cells. In 1944, Jackson and Parker
proposed the first comprehensive classification of the tumor
(Table 1). However, this classification was subsequently
found to be clinically irrelevant because most patients
belonged to the granulomatous subtype and the response to
treatment varied greatly from case to case.
In 1956, Smetana and Cohen identified a histopatholog-
ical variant of granulomatous Hodgkin disease (HD), which
had a better prognosis and was characterized by sclerotic
changes; this variant was termed “nodular sclerosis HD”
in the classification proposed by Lukes, Butler, and Hicks
in 1964 (Table 1). This last classification, simplified at the
Rye conference in 1965 (Table 1), has been used routinely
over the past 35 years because of the high interpersonal and
intrapersonal reproducibility and good clinicopathological
correlations.
In 1994, in the light of morphological, phenotypic,
genotypic, and clinical findings, HL was listed in the revised
European-American lymphoma (REAL) classification [16]
and subdivided into two main types: lymphocyte predom-
inant (LP-HL) and common HL (CHL). CHL included
the following subtypes: nodular sclerosis (NS-CHL), mixed
cellularity (MC-CHL), lymphocyte depletion (LD-CHL),
and the diﬀuse form of the lymphocyte rich CHL (LR-
CHL) (Table 1). This approach has finally been adopted by
the recently developed World Health Organisation (WHO)
scheme (Table 1), which has promoted LR-cHL from a
provisional entity to an accepted entity [1, 9, 17–20]. In
this classification, the nodular form of LR-cHL has been
included, as proposed by the European lymphoma task force
[1, 9, 12, 17–22].
It is noteworthy that HL subtyping should be performed
only in lymph node biopsies at the onset of the disease;
in fact, chemotherapy and/or radiotherapy modify the
histopathological picture by inducing a lymphocyte-depleted
pattern.
2. Lymphocyte Predominant Hodgkin
Lymphoma (LP-HL)
LP-HL represents 4%–5% of all HL cases [1, 9, 17–20] and
diﬀers greatly from the common type in terms of morphol-
ogy, phenotype, genotype, and clinical behavior. The only
Table 1: Hodgkin’s lymphoma (HL) classification schemes.
Jackson and Parker classification
Paragranuloma
Granuloma
Sarcoma
Lukes and Butler classification
Lymphocytic and/or histiocytic, nodular
Lymphocytic and/or histiocytic, diﬀuse
Nodular sclerosis
Mixed cellularity
Diﬀuse fibrosis
Reticular
Rye conference classification
Lymphocyte predominance
Nodular sclerosis
Mixed cellularity
Lymphocytic depletion
Revised European-American lymphoma (REAL) classification
Nodular lymphocyte predominance nodular/diﬀuse
Classic HL
Nodular sclerosis
Mixed cellularity
Lymphocyte depletion
Lymphocyte rich classic HL diﬀuse (provisional entity)
World Health Organisation scheme
Nodular lymphocyte predominant HL
Classic HL
Nodular sclerosis HL (grades 1 and 2)
Lymphocyte-rich classic HL∗
Mixed cellularity HL
Lymphocyte-depleted HL
Unclassifiable classic HL
∗
This includes a nodular (common) and a diﬀuse (rare) form in contrast to
the REAL classification.
feature shared by LP-HL and cHL is the low number of
neoplastic cells. For a long time, after the adoption of the
Lukes classification, the tumor was also called “nodular
paragranuloma”, a designation coined by the Kiel group
[23], based on the term “paragranuloma” introduced much
earlier by Jackson and Parker. This designation intended to
underline the diﬀerences existing between this type of HL
and the remaining ones.
2.1. Clinical Findings. LP-HL displays features that are not
generally encountered in cHL, which makes its clinical
picture closer to that of “indolent” B-cell lymphoma [24].
First, it has a unimodal age distribution, with a single
peak in the 4th decade, which contrasts with the two peaks
of cHL, one in the 3rd and the other in the 7th decade
[24]. The disease usually aﬀects single cervical, axillary, or
inguinal nodes rather than groups of nodes. Bone marrow
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Figure 2: Histopathological features of lymphocyte predominant Hodgkin lymphoma (LP-HL). At morphology (GIEMSA staining), it is
possible to appreciate the nodular morphology (GM-I) and the typical LP cells (GM-II, arrow). At immunophenotyping, it is typically
CD15−, CD30−, EMA+, CD45+, CD20+, and possibly (10%–20% cases) IgD+ (Olympus BX41 microscope, Olympus CAMEDIA C-7070
camera, magnification ×400, colours balanced after acquisition with Adobe Photoshop).
involvement is found only occasionally during staging
procedures in patients whose disease appears to be limited
to a single node [24]; this pattern of spread diﬀers from the
orderly progression classically seen in cHL [25]. Involvement
of the thymus is most unusual, unlike the other types
of HL [24]. The tumor has a very indolent course, with
prolonged disease-free intervals, despite a high rate of late
relapses, which usually respond well to treatment [24, 26].
In addition, it can be associated with a diﬀuse large B-cell
lymphoma (DLBCL), which has a more favourable outcome
than de novo large B-cell lymphomas [24, 27].
2.2. Morphological Findings. In most instances, the growth
is—at least in part—nodular (Figure 2), with the occur-
rence of a diﬀuse variant of the process being very rare
[1, 9, 17–20, 24, 28]. The neoplastic population consists
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Table 2: Classification of LP-HL.
Classical nodular pattern, B-cell rich
Serpiginous/interconnected nodular pattern
Nodular, with prominent extra nodular B cells
Nodular, with T-cell rich background
Diﬀuse pattern (TCRBCL-like)
Diﬀuse, “moth eaten” with B-cell-rich
background
According to Fan et al., (Am J Surg Pathol 2003).
of large elements, called L&H (lymphocytic/histiocytic) or
popcorn cells [24] (Figure 2). The former term has almost
completely been abandoned in the light of the confirmed
lymphoid derivation of the tumor and substituted by the
LP (lymphocyte predominant) one in the IV edition of the
WHO classification [1, 3–7, 9, 12, 17–20]. LP cells show
nuclei resembling those of centroblasts, with a polylobular
profile, finely dispersed chromatin, and small nucleoli, which
are often adjacent to the nuclear membrane (Figure 2)
[24]. Their cytoplasmic rim is narrow and basophilic when
stained with Giemsa. Occasionally, neoplastic elements dis-
play the features of RS cells and/or of lacunar cells of
NS-cHL and are associated with minimal sclerosis [24];
under these circumstances, immunophenotyping plays a
fundamental role in the diﬀerential diagnosis between LP-
HL and LR- cHL or NS- cHL. The reactive milieu consists
of small lymphocytes with some plasma cells and epithelioid
elements, which at times become so numerous as to mimic
a histiocyte rich, large B-cell lymphoma (HCRBCL) [29].
According to the histological pattern, Fan et al. in 2003
proposed a subclassification of LP-HP into 6 categories
(Table 2).
2.3. Progressively Transformed Germinal Centres. Progres-
sively transformed germinal centres (PTGCs)—first de-
scribed by Lennert in collaboration with Mu¨ller-Hermelink
in 1978 [30]—are a peculiar form of follicular hyperplasia,
which can be confused with LP-HL.
PTGCs occur in children and young adults, and these
individuals reveal a slightly higher risk of developing LP-
HL than the average population. PTGCs can precede, concur
with, or follow LP-HL [23].
On morphological grounds, PTGCs are two to three
times larger than reactive follicles and predominantly consist
of small lymphocytes, mainly mantle cells, intermingled
with some centroblasts and follicular dendritic cells (FDCs).
PTGCs can be diﬀerentiated from LP-HLs because of the lack
of LP elements and their cytological composition; they are
composed of a mixture of B (CD20+) and T (CD3+) cells,
histiocytes, and FDCs, which overall produce a “moth eaten”
appearance [30, 31].
2.4. Phenotypic Findings. The neoplastic cells have a char-
acteristic profile, which diﬀers greatly from that of cHL
[12, 16, 22]. In particular, they are CD45+, CD20+,
CD22+, CD79a+, J chain+/−, epithelial membrane antigen
(EMA)+/−, and CD15−. CD30 positivity is rare and, when
detected, weak (Figure 2). Interestingly, a certain number
of extrafollicular reactive blasts (smaller than the popcorn
cells) are detected by the anti-CD30 antibodies; in the past,
they have been misinterpreted as tumoral elements [22].
Popcorn cells regularly express OCT2 and BOB.1 [32]. The
transcription factor Oct2 and its coactivator BOB.1 play a
basic role in immunoglobulin synthesis by triggering the
specific gene promoter [33] and are excellent tools for the
identification of neoplastic cells in LP-HL, in addition to
their diﬀerentiation from those of cHL, which are negative in
almost all instances [32]. Although LP-HL is characterized by
a more preserved B-cell phenotype compared to the classical
variant, a certain degree of defectivity was described by
Tedoldi et al. [34] that observed a downregulation of several
markers associated with the B-cell lineage (CD19, CD37,
CD79b, and LYN) and with the germinal center maturation
stage (CD10, LCK, and PAG).
The derivation of the tumor from germinal centres is
supported by the following:
(1) the expression of the BCL6 gene product (Figure 3)
[35], CD40, and CD86 by neoplastic cells [36, 37];
(2) the occurrence of numerous CD4+/CD57+/PD1 T
cells surrounding the popcorn cells, as seen in normal
germinal centres and PTGCs (Figure 4) [37];
(3) the presence of an FDC meshwork (CD21+/CD35+)
within the nodules [38];
(4) the global gene expression profile (see below) [39].
CD4+/CD57+/PD1 small lymphocytes resetting around
typical CD20+/BCL6+ LP cells are indeed useful for the
diﬀerential diagnosis with PTGC, LR- cHL, and TCRBCL
(Figure 4). In addition, staining for LSP1, PU1, and IgD
has to be considered. The latter, in particular, identifies a
subgroup of cases (10%–20%) with peculiar epidemiologi-
cal, phenotypical (IgD+, CD38+, CD27−, and IgM−), and
clinical features [40, 41] (Figure 2).
2.5. Genetic Findings. Further evidence indicating that the
tumor is derived from germinal centre B cells has been
provided by recent molecular studies, based on the single
cell polymerase chain reaction (PCR) [2–7, 12]. These
studies have shown that LP cells in any given case represent
monoclonal populations derived from germinal centre B
cells, owing to the consistent occurrence of monoclonal
IGH gene rearrangements and the high load of somatic
mutations within variable region genes. Ongoing mutations
are detected in about half of LP-HL cases; this finding—
not observed in cHL—identifies mutating germinal centre
cells as the precursors of the neoplastic elements [3, 6]. The
pattern of mutation within these gene segments suggests that
tumoral cells, their precursors, or both have been selected
for expression of functional antigen receptors [3, 5, 6]. In
addition, aberrant somatic hypermutation targeting PAX5,
RHOH/TTF, PIM1, and MYC has been recorded in 80% of
LP-HL cases, further supporting the GC derivation [42].
Recently, gene expression profile (GEP) analysis carried
on isolated neoplastic cells indicated that LP cells possibly
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Figure 3: Immunophenotyping of Hodgkin lymphoma. Immunostains for BCL6, PAX5, BCL2, and p53 are shown. Please note positive
staining in the diagnostic cells (arrows).
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Figure 4: The reactive “milieau” in Hodgkin lymphoma. Mast cells and regulatory T cells populate the HL microenvironment showing
spatial interaction with RS cells. Immunohistochemical staining for PD-1 and FOXP3 highlights the presence of several regulatory T cells
intermingling with RS cells (arrows). Double immunohistochemistry for CD30 (yellow/brown) and mast cell tryptase (purple) shows the
tight interaction of mast cells with RS cells.
originate from germinal center B-cells at the transition
to memory B cells [39]. In addition, LP cells showed a
surprisingly high similarity to the tumor cells of TCRBCL
and cHL, a partial loss of their B cell phenotype, and deregu-
lation of many apoptosis regulators and putative oncogenes.
Importantly, LP cells turned out to be characterized by
constitutive NFκB activity and aberrant extracellular signal-
regulated kinase signalling [39].
Finally, to date, in situ hybridisation studies with Epstein-
Barr virus (EBV) early RNA 1/2 (EBER1/2) probes, in ad-
dition to conventional Southern blot, PCR, and immuno-
histochemistry for the latent membrane protein 1 (LMP-1),
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have never detected EBV in the LP cells of LP-HL, in con-
trast to the neoplastic component of cHL [43, 44]. Isolated
small lymphocytes from the reactive background carry EBV
infection in 25% of cases of cHL [19].
3. Classic HL
This variant comprises about 95% of all HL cases and shows
a typical bimodal age distribution, with a peak at 10–35
years of age and a second peak in late life [1, 9, 17–20].
It is characterized by a series of clinical, morphological,
phenotypic, and genotypic features, which are integrated
by specific findings in the four subtypes of the process
(nodular sclerosis, mixed cellularity, lymphocyte depletion,
and lymphocyte rich).
3.1. Clinical Findings. cHL usually presents in the laterocer-
vical lymph nodes, with peripheral extranodal involvement
being very rare. About 50% of patients are in stage I or
II. A mediastinal mass is seen in most patients with NS-
cHL, at times showing the characteristics of “bulky” disease.
Systemic symptoms—fever, night sweats, and body weight
loss—are detected in approximately 25% of patients. In
contrast to earlier reports, the histological subtype is not
regarded as a major prognostic indicator. Without treatment,
cHL has a moderately aggressive clinical course. With the
present treatments, 70%–80% of cases show long-term
survival [45–49].
3.2. Morphological Findings. In cHL, typical Hodgkin’s
and Reed-Sternberg (H&RS) cells (Figure 1) can be easily
detected; their number (from few to many) diﬀers from case
to case. They may be associated with peculiar cell variants
and are found within an inflammatory milieu, related to the
histological subtype (see below). The lymph node structure
is largely eﬀaced although remnants of normal follicles can
be detected in some cases. The type of structural alteration is
indeed characteristic in NS-cHL.
3.3. Phenotypic Findings. In 1982, Schwab et al. described
a new monoclonal antibody, termed Ki-1, whose reactivity
seemed restricted to H&RS cells and a small subset of
normal lymphocytes with perifollicular location. However,
the extensive application of the antibody showed that it was
not specific to H&RS cells, as originally thought, but reacted
with a variety of lymphoid tumors, including anaplastic
large-cell lymphoma (ALCL) [50–52] and nonlymphoid
tumors such as embryonic carcinoma, pancreatic carcinoma,
nasopharyngeal undiﬀerentiated carcinoma, and malignant
melanoma [14, 53, 54]. Therefore, the immunophenotypic
diagnosis of HL should always be based on the application of
a panel of antibodies, including reagents against cytokeratins,
melanoma-associated antigens, carcinoembryonic antigen,
and placental alkaline phosphatise [14].
Expression of the CD30 molecule by H&RS cells is seen
in more than 98% of cHLs (Figure 1) although the intensity
of the immunostaining can vary from one case to another,
and even within the same case. Interestingly, the antigen is
masked by fixation (especially prolonged fixation in formalin
or fixation in B5); thus, very eﬃcient antigen retrieval
techniques are required to achieve reliable results in routine
material [55]
Notably, the CD30 molecule has also been proposed
as a possible target for specific antibodies conjugated with
plant toxins and administered to patients with cHL for
therapeutic purposes; preliminary studies have shown these
immunotoxins to have remarkable cytotoxic activity [56–58].
CD15 is another valuable marker for H&RS cells
(Figure 1) and is detected in about 80% of patients with cHL
[51, 59]. CD15 is characteristic, but not specific, for H&RS
cells because it can be detected (although rarely) in B and T
cell lymphomas and in nonlymphoid tumors [51, 59, 60].
H&RS cells usually lack CD45 and EMA expression [61–
64], whereas B and T cell markers are seen in a proportion of
cases. In particular, CD20 (Figure 1) is found in 30%–40% of
cHL cases (usually EBV negative) [63], and CD79a is found
even less often [65–67]. Positivity (usually weak) for one or
more T cell marker is detected in a minority of H&RS cells
in some cases [68, 69]. Under these circumstances, single
cell PCR studies have so far shown T-cell receptor (TCR)
gene rearrangement in only three instances, with clonal Ig
gene rearrangements occurring in most cHL cases with T-
cell marker expression [8, 70]. In contrast to that seen in
LP-HL, the elements of cHL show variable expression of the
BCL6 molecule [17]. In addition, they are usually positive
for PAX5/BSAP and IRF4 and negative for BOB.1 and OCT2
[7, 8, 71].
Antibodies against the nuclear-associated antigens Ki-67
and proliferating cell nuclear antigen (PCNA) stain most
H&RS cells, suggesting that a large number of neoplastic cells
enter the cell cycle [72, 73]. However, in spite of this, tumor
cells do not rapidly overwhelm the reactive component
[72, 73]. This phenomenon has found a satisfactory expla-
nation in the studies of Leoncini and coworkers, who have
shown that H&RS cells have a defect in cytokinesis [74]. In
fact, only aminority of the cycling elements undergo eﬀective
mitosis, and a proportion of the cells that do not enter into
the cell cycle undergo apoptosis, a step partly regulated by the
BCL2 and p53 gene products [74].
On prognostic grounds, it has also been proposed that
chemoresistance and the tendency to relapse are influenced
by the expression of BCL2, p53, p21, and PCNA [75, 76]
(Figure 3). In general, tumors with H&RS cells showing
expression or overexpression of one or more of these
molecules seem to have a poor response to the treatment
and/or short survival time.
3.4. The Babel of HL Microenvironment. In classical Hodg-
kin’s lymphoma, the tumor-associated microenvironment
endows a central role, as far as the pathobiology, diagnosis,
prognosis, and even therapy are concerned. Inmost HL cases,
nonneoplastic cellular components, comprising immune
and stromal cells, account for the vast majority of the tumor
burden (usually more than 90%). In such a setting, in
which neoplastic cells are dispersed among reactive elements,
the “pressure” of the microenvironment over the neoplastic
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clone may be perceived on mere morphology (Figure 1).
Indeed, a strong reciprocal influence exists between RS cells
and the diverse types of reactive cells of the microenviron-
ment.
The composition of the cellular milieu associated with
HL includes cells of the innate and adaptive branches of the
immune system, such as granulocytes, macrophages, mast
cells, T and B lymphocytes, plasma cells, and mesenchymal
elements, namely endothelial cells, adventitial reticular cells,
fibroblasts, and follicular dendritic cells forming an intricate
vascular and perivascular meshwork.
The composition and amount of reactive components
may vary significantly among the diverse histological sub-
types of classical HL and even at discrete stages of the
disease course. For example, the reactive background is most
pleomorphous in HL cases of the mixed cellularity histo-
type, where inflammatory elements eﬀace the lymph node
architecture, while it is mainly composed of lymphocytes
organized within preserved or regressed lymphoid follicles in
cases of the lymphocyte-rich type [1, 9, 17–20]. In these two
conditions, profoundly diﬀerent interactions between neo-
plastic cells and the surrounding reactive microenvironment
can be predicted. In the nodular sclerosis variant, the pres-
ence of a prominent mixed inflammatory background may
be progressively reduced by the accumulation of collagen
fibrosis suggesting a dynamic process of tissue remodelling
[1, 9, 17–20].
H&RS cells have a major role in the orchestration of
the microenvironment milieu associated with HL. They
can directly induce the recruitment of several immune cell
types from the peripheral circulation and also trigger the
local expansion of diverse cellular subsets. Specifically, RS
cells synthesize a whole plethora of soluble mediators with
chemotactic activity such as the cytokines and chemokines
IL-5, IL-8, IL-9, CCL-5, and CCL-28 involved in the
recruitment of granulocytes, mast cells and macrophages,
and IL-7, CCL-5, CCL-17, CCL-20, and CCL-22, eﬀectors
of lymphocyte recruitment and expansion [77, 78]. Recruit-
ment of infiltrating immune cells is also boosted by reactive
cells themselves and particularly by macrophages and mast
cells synthesizing CCL-3, CCL-4, and CCL-8 chemokines
[78, 79]. RS cells and recruited or locally-expanded immune
and stromal cells give rise to a complex and dense network of
signals mediated by direct cell contact and soluble mediator
synthesis. Most of these signals have their relevant final
eﬀect in the delivery of a prosurvival feedback to RS cells.
These include the engagement of surface CD40 and CD30
molecules expressed on RS cells by CD40L-expressing T
lymphocytes, NK cells, and mast cells, which are often
found surrounding RS cells, and by CD30L expressed on
B lymphocytes, granulocytes, macrophages, and mast cells
[80, 81].
Besides directly interacting with neighbouring cells
through these pivotal axes, RS cells are able to sense growth
and survival signals coming from the growth factor milieu,
owing to the expression of a broad range of receptors
including IL-7R, IL-9R, IL-13R, TACI, and CCR5 [78]. The
combination of paracrine and autocrine mechanisms grants
a high degree of redundancy to RS cell stimulation, thus
making any attempt of therapeutic interference with these
mechanisms challenging. Along with growth factors, also
proinflammatory cytokines and mediators can sustain RS
cell expansion through the activation of pathways converging
into the NFkB hub, such as those triggered by IL-6R,
TACI, RANK, TNFR-1, Cys-LT receptors, and NOTCH-
1 engagement [82]. These proinflammatory spurs may be
either derived from the microenvironment (e.g., leukotriene
production by mast cells and NOTCH-1 ligand expression
by stromal cells) or originate from both RS cells and reactive
elements (e.g., IL-6, TNF).
If RS cells are the main beneficiaries of this Babel of cellu-
lar and molecular interactions, they are not the sole targets.
Indeed, the stromal components of the microenvironment
may be induced towards significant changes characterized
by the proliferation of follicular dendritic cells (FDC)
and fibroblasts and microvascular sprouting [1, 9, 17–20].
Stromal changes can be directly supported by RS cells
through the synthesis of cytokines active on the stroma,
such as IL-6, IL-7, IL-8, IL-13, and TNF. Nevertheless, in
the stromal remodelling of HL-infiltrated tissues, a major
role is played also by cells other than RS ones, mostly
macrophages and mast cells that are particularly active
in regulating angiogenesis and extracellular matrix (ECM)
deposition. Moreover, stromal FDCs, which are a relevant
source of stimulatory signals for the HL neopastic clone
of GC derivation, as well as for reactive T and B cells, are
mainly expanded through the synthesis of CXCL-13 and IL-
21 by follicular helper T cells expressing PD-1 and CXCR-5
[83].
The influence of the cellular components of the microen-
vironment and that of the elaborate network of interactions
they produce, on the clinical course of HL, has progressively
emerged over the past decades. In particular, the detrimental
contribution of mast cells and CD68+ macrophages to
HL patients’ survival has been clearly established [84, 85].
Though the precise mechanisms through which these cell
types favour neoplastic clone progression are not entirely
characterized, they are likely linked to the ability of mast cells
andmacrophages to induce andmaintain a proinflammatory
microenvironment. In this light, we could hypothesize that
the contribution of Tregs to HL might be function of the
microenvironment polarization. Indeed, Tregs may limit the
inflammatory spur of other cells of the immune system
(including T eﬀectors) by releasing IL-10 and TGF-b, and
this beneficial eﬀect may prevail over the impairment of
an eﬀective T-cell-mediated response, as far as the outcome
of HL is concerned (Figure 5). Nevertheless, when the
HL-associated environment is diverted towards marked
inflammation owing to the abundant presence of mast
cells and macrophages, the regulatory function of Tregs
may prove inadequate to restore the balance between pro-
and anti-inflammatory stimuli, and Tregs can even boost
inflammation through TGF-b release and Th17 generation
(Figure 3). Under these circumstances, a direct role for mast
cells in the Treg contrasuppression and Th17 deflection can
be envisaged as both mast cells and Tregs populate HL-
infiltrated areas, and their interaction is therefore possible
(Figure 4).
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Figure 5: Schematic representation of the reciprocal contribution of mast cells (MC), eﬀector T cells (Teﬀ), and regulatory T cells (Treg) to
the HL-associated immunological microenvironment. (a)Mast cells, as other innate immune players directly sustain RS cell proliferation and
proinflammatory mediator synthesis. (b) This eﬀect is boosted by Teﬀ that contributes to mast cell activation and amplifies the inflammatory
spur. (c) Treg can interfere with the activation status of both Teﬀ and MC through the OX40/OX40L axis and TGF-β release eventually
limiting the delivery of the proliferation/survival signal to RS cells. (d) However, when the microenvironment is diverted towards marked
inflammation owing to the abundant presence of activated MC, the regulatory function of Treg may prove inadequate to restore the balance
between pro- and anti-inflammatory stimuli, and Treg can even boost inflammation through TGF-β release and Th17 generation.
3.5. Genetic Findings. The origin of the RS cells of HL has
long been a mystery [86]. As previously discussed in the LP-
HL section, micromanipulation of single RS cells from tissue
sections and PCR analysis of the cells for rearranged IGH
genes have shown that most of both LP-HL and cHL cases
represent clonal populations of B-cell lineage [2–7, 12]. In
contrast to that seen in LP-HL, ongoing mutations of IGH
genes are not detected in cHL [7]. On the other hand, the
presence of aberrant somatic hypermutation (ASH) targeting
PAX5, RHOH/TTF, PIM1, or MYC in 50% of cases further
supported the origin from GC cells [42]. Based on the
results obtained in a small series of cases, emphasis was
instead given to the occurrence of mutations resulting in
stop codons within originally functional variable region gene
rearrangements [6]. Such mutations are expected to occur
in variable region genes of germinal centre B cells, but
under physiological conditions, “crippled” germinal centre
cells (incapable of functional antibody expression) rapidly
undergo apoptosis. RS cells might also have other mutations
that can be crippling but may not be easy to find (e.g.,
replacement mutations interfering with antigen binding or
heavy, and light-chain pairing) [6]. However, by analyzing
a large number of cases, Marafioti et al. found that crippling
mutations are absent from 75% of cHL s, indicating that
crippling mutations cannot be responsible for the general
absence of the IGH transcripts [7], which might be the
result of downregulation of the synthesis of the transcription
factors BOB.1 and OCT2 (see above) [7, 8].
Recently, some studies have pointed to the possibility
that the nuclear transcription factor NFκB is involved
in the protection of H&RS cells from apoptosis, which
would be expected because of their inability to produce
immunoglobulins [87]. The persistent activation of NFκB in
H&RS cells might be caused by defects in members of the
IκB family, which are the natural inhibitors of NFκB [87–
90], or by the aberrant activation of IκB kinase [91]. To this
regard, interestingly, it was recently shown that the tumor
suppressor gene TNFAIP3, encoding for A20, a negative
regulator of NFκB, is frequently mutated in cHL, leading to
NFκB constitutive activation [92]. Conversely, it appeared to
be not aﬀected in LP-HL [93].
In contrast, despite the frequent expression/overexpres-
sion of p53 by neoplastic cells, no mutations of exons 4–8 of
the TP53 gene have been detected in H&RS cells [94].
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No specific cytogenetic abnormalities have been reported
in cHL because aberrations vary from one case to another,
with frequent intraclonal variability, thus suggesting chro-
mosomal instability [95]. Some tumors show 14q alter-
ations, as seen in B-cell lymphomas, but without the
occurrence of the t(14;18) translocation [95]. On the other
hand, recent studies, by using high-throughput techniques,
identified recurrent imbalances with correlations to treat-
ment outcome [96]. In particular, genomic loci containing
genes encoding for NFkB molecules as well as proteins
involved in drug resistance (i.e., ABCC1) were found to
be frequently altered in microdissected H&RS cells, such
abnormalities correlating with the overall survival [96].
Interestingly, a recent study documented the association
between 9p24.1 copy number and PD-1 ligand expres-
sion in cHL and the frequent involvement of the Janus
kinase 2 (JAK2) locus. Thus, the PD-1 and JAK2 path-
ways were defined as potential novel therapeutic targets
[97].
In addition, recently, by using comparative genomic
hybridization arrays (aCGH) on HL cell lines, a complex
patterns of rearrangements was demonstrated including 35
previously uncovered aberrations [98]. Among others, the
homozygous deletion of 15q26.2, amplification of the STAT6
gene, and a 2.35Mb deletion at 16q12.1, putatively defining
a small critical region for the recurrent 16q deletion in cHL,
appeared to be of interest. Notably, the latter region contains
the CYLD gene, a known suppressor gene of the NFkB
pathway [98].
Subsequently, an aCGH study applied to primary cHL
samples identified the recurrent involvement of several
regions by either amplification (2p12-16, 5q15-23, 6p22,
8q13, 8q24, 9p21-24, 9q34, 12q13-14, 17q12, 19p13, 19q13,
and 20q11) or losses (Xp21, 6q23-24, and 13q22) [99].
Notably, several gained regions included genes known to
be constitutively expressed in cHL. Among these, gains of
STAT6 (12q13), NOTCH1 (9q34), and JUNB (19p13) were
confirmed [99].
EBV studies reveal viral integration in the genome of
cHL tumor cells in a variable proportion of patients (20%–
80%), depending on the histotype. In particular, in Western
countries, 20%–40% of NS and LD cases and 50%–75%
of MC cases show expression of LMP-1 and/or EBER1/2,
(Figure 1) but not EBV- encoded nuclear antigen 2, thus
showing a pattern characteristic of latency type II EBV
infection [100, 101]. Interestingly, these figures can vary
greatly according to the geographical area examined, as
recently shown by Leoncini and coworkers, who found
significant diﬀerences in the incidence of EBV between
patients with cHL from Kenya and Italy (92% versus 48%)
matched for age and histotype [102]. The type of EBV strain
also varies between diﬀerent geographical areas; in developed
countries strain 1 prevails, whereas strain 2 is most prevalent
in developing countries [103]. HLs that are positive for
EBV at diagnosis are usually also positive at relapse, with
persistence of the same EBV strain [104]. The exact role
of EBV in the pathogenesis of cHL (transforming agent?
cofactor for the maintenance of malignant growth?) is still
open to question [44].
Recently, a couple of gene expression profile (GEP)
studies dealt with HL, by focusing on the identification
of novel prognostic features. First, Sanchez-Aguilera et al.
[105] have identified a gene signature able to distinguish
patients with classical Hodgkin lymphoma with good and
poor prognosis; it consists of gene expressed by neoplas-
tic cells related to growth/apoptosis and genes of tumor
microenvironment involved mainly in immune response and
matrix remodelling. The GEP results has been subsequently
validated by immunohistochemistry in and independent
series of samples, using antibody directed against products
of selected representative genes (SAP, STAT1, RRM2, CDC2,
MAD2L1, ALDH1A1, Top2α, and PCNA). This suggests that
both the biology of neoplastic cells and the characteristic
of the background could be determining factors for the
clinical behaviour of the neoplasia and the success of
therapy. The possible identification in the near future of
novel biological markers able to identify patients with
diﬀerent prognosis would be a dramatic improvement in HL
patients management. In fact, at present, the best prognostic
indicator is probably represented by PET-scan evaluation
after two course of chemotherapy [106]. As a matter of
fact, patients are identified as high risk, requiring diﬀerent
therapeutic strategies only after having received a significant
(and useless) toxic load.
More recently, Steidl et al. studied a large series of HL and
identified tumor microenvironment as a major determinant
of clinical outcome [85]. In particular, a molecular signature
representative of macrophage infiltration was significantly
associated with overall survival [85]. Importantly, such
finding was confirmed in an independent cohort of patients
by studying the tumor-associated macrophages by immuno-
histochemistry (CD68 staining) [85].
3.6. Nodular Sclerosis
3.6.1. Morphological Findings. NS is the most frequent
subtype of cHL in Italy and the USA, where it corresponds
to 75%–80% of all HL cases; however, the incidence of
these subtypes varies greatly among other geographical areas
[107–109]. As stated by Lukes et al. in 1966, the tumor is
characterized by sclerosis, lacunar cells, and nodular pattern.
Sclerosis. Fibrotic phenomena always occur in NS- cHL;
they more often correspond to the formation of broad
collagen bands, which originate from a regularly thickened
lymph node capsule (Figure 1) and subdivide the lymphoid
parenchyma into large nodules, at times visible at gross
examination. Fibrotic tissue displays a typical birefractive
green colour at polarised light microscopy, a finding never
seen in LD-cHL.
Lacunar Cells. These cells are characteristic of NS-HL. Lukes
et al. originally described them as large elements with
polylobular nuclei, small-to-medium-sized nucleoli, and a
wide rim of clear or slightly acidophilic cytoplasm, which
is very sensitive to formalin fixation. This last factor causes
perinuclear condensation of the cytoplasm, which remains
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connected to the cell membrane via some narrow filaments,
forming empty “lacunar” cytoplasmic spaces. In fact, lacunar
cells display a much higher degree of pleomorphism than
was originally thought; they may be unilobular, multilobular,
and/or showing huge nucleoli, which are indeed similar
to those of typical RS cells. This morphological variability
seems to depend on the characteristics of the inflammatory
component present in each case [110]. Although lacunar
cells are easily detected, H&RS cells are rare and their
identification may involve a long search. Finally, it should
be stressed that some neoplastic elements appear to be
“mummified” because of apoptotic changes.
Nodular Pattern. The nodules, which should be detected in
at least part of the lymph node involved, can contain foci of
necrosis and can be very variable in terms of inflammatory
cell component (from lymphocyte predominance to lym-
phocyte depletion).
NS-CHL: Cellular Phase. In NS- cHL, the amount of col-
lagen fibres varies greatly from one case to another. In the
so-called cellular phase, there is a clear cut tendency to
nodule formation without overt collagen band deposition.
However, there are typical lacunar cells, often located at the
periphery of the nodules or around residual follicles. The
reactive component mainly consists of small lymphocytes
bearing the phenotype of mantle B cells (CD20+, CD79a+,
CD5+, IgM+, IgD+, and CD3−) [108, 111]. The secretion
of cytokines by neoplastic cells is currently believed to cause
the progressive attraction of T cells, histiocytes, plasma cells,
and eosinophils, which give rise to nodules replacing the pre-
existing follicles and produce the typical pattern of NS-cHL.
Within the nodules, there are numerous FDCs, which seem
to represent a favourable prognostic indicator [112, 113].
NS-CHL Syncytial. The term “syncytial” NS- cHL was
coined by Butler in 1983 and then reproposed by Strickler
et al. in 1986 [114]. This variant is thought to form 16%
of all NS-cHL cases [115] and to run a more aggressive
clinical course [109, 115], as suggested by the occurrence
of mediastinal bulky disease and stage III/IV in 88% of the
patients. At light microscopy, it is characterized by large
sheets of neoplastic cells (partly with a lacunar appearance),
which may undergo central necrosis [114]. The diﬀeren-
tial diagnosis (which includes non-Hodgkin’s lymphoma,
metastatic melanoma, carcinoma or sarcoma, thymic carci-
noma, or germ cell tumors) requires the application of an
adequate panel of antibodies, which allows the identification
of the characteristic phenotype of the tumoral cells: CD3−,
CD15+, CD20−/+, CD30+, CD45−, CD79a−, cytokeratin
negative, PLAP−, protein S-100−, HMB.45 melanoma-
associated antigen negative, EMA−, and ALK−.
Histological Grading of NS-HL. The British national lym-
phoma investigation (BNLI) group has repeatedly proposed
that NS-cHL should be subclassified into two grades: grade
II tumors seem to represent 15%–25% of all NS-cHL cases
and to run a more aggressive clinical course [111, 116, 117],
a finding not confirmed by all studies [112, 118, 119]. In the
recently developed WHO scheme, the BNLI grading system
has been maintained to test its real prognostic value on larger
series [1, 9, 17–20]. It is based on the degree of cellularity
of the nodules, the amount of sclerosis, and the number and
atypia of neoplastic cells. The term grade II is applied to cases
showing one of the three following patterns:
(1) more than 25% of the nodules have a cellular com-
position consistent with the pleomorphic or reticular
subtype of NS-cHL /LDV;
(2) more than 80% of the nodules show a fibrotic or
fibrohistiocytic composition;
(3) more than 25% of the nodules contain numerous
large bizarre or anaplastic cells, in the absence of
depletion of the reactive small lymphoid component.
3.7. Mixed Cellularity. This histotype was originally
described by Lukes et al. as intermediate between LR and
LD- cHL. Later, Lukes included in this category all the
cases that according to his criteria remained unclassified,
transforming it into a “basket”.
About 15%–25% of cHL cases belong to this category.
The histological picture is characterized by diﬀuse growth
with a frequent paracortical location. The capsule is not often
involved and necrosis seldom occurs. The term MC-cHL
reflects the cellular composition of the reactive milieu, which
consists of plasma cells, epithelioid histiocytes, eosinophils,
and T cells (CD3+, CD57−), which form rosettes around
neoplastic elements (Figure 4). The tumor cells correspond
to H&RS cells and are numerous and easy to find, without
lacunar or popcorn variants. Some neoplastic elements, as
in the NS subtype, appear to be “mummified” because of
apoptotic changes.
3.7.1. Morphological Variants of MC
Interfollicular Variant. This variant is rarely seen and prob-
ably represents partial lymph node involvement by HL.
It is characterized by the occurrence of numerous H&RS
cells around reactive follicles, which display germinal centres
either in the second phase of development [120] or in
regressive transformation. These germinal centres usually
resemble those seen in hyaline-vascular Castleman’s disease
and are probably related to the release of cytokines, such
as IL-6 [121], by H&RS cells [122]. This unusual variant of
MC-HL should be taken into consideration to avoid possible
confusion with follicular hyperplasia or Castleman’s disease
[120, 123].
Epithelioid Cell Rich Variant. This variant is relatively com-
mon and shows a prominent epithelioid cell reaction with
granulomata formation and occasional Langhans cells. In
this context, typical H&RS cells are always detected, at times
after a laborious search. It should be diﬀerentiated from
the so-called Lennert’s lymphoma because of the dramatic
diﬀerences in terms of treatment between the two entities
[111, 124].
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3.8. Lymphocyte Depletion. This variant is very rare, account-
ing for about 1% of HL cases, and shows the worst clinical
behavior and prognosis. In most instances, it presents in
stage III-IV. B-cell symptoms and bone marrow involvement
are detected in 50% of cases [125, 126]. At microscopic
examination, it is characterized by paucity of the lymphoid
component, absolute or relative abundance of RS cells, and
variable fibrotic reaction. According to Lukes and Butler,
two subtypes of LD-HL can be distinguished: fibrotic and
reticular/sarcomatous.
Fibrotic Variant. This results in the complete eﬀacement
of the nodal structure with possible capsule preservation.
At microscopic examination (Figure 1), it shows the fol-
lowing distinctive features: (1) low cellular density with
scarce, although variable, amounts of small lymphocytes;
(2) prominent diﬀuse reticulin fibre formation without
organised birefringent collagen bands [123], which tend to
include single neoplastic elements and are associated with
the deposition of amorphous material (precollagen) around
sinusoids; (3) a high variability in the number of H&RS
cells, the detection of which sometimes requires a long and
labourious search.
At low power, the histopathological picture can resemble
the depletion phase of HIV lymphadenopathy [127]; there-
fore, careful node examination is needed to make a firm
diagnosis [128].
Reticular or Sarcomatous Variant. This is characterized by
extremely large numbers of H&RS cells, some of which
appear to be “mummified”. The growth results in diﬀuse
eﬀacement of the normal lymph node structure; small
lymphocytes, plasma cells, histiocytes, and granulocytes are
scanty; foci of necrosis are usually encountered, although
their extent varies from one case to another.
3.9. Lymphocyte Rich Classic Hodgkin’s
Lymphoma. Several reports have underlined the existence of
HL cases with a lymphocyte predominant background, but
diﬀering from the prototypic description of LP-HL because
of the presence of some eosinophils, sclerosis, typical H&RS
cells, or aberrant phenotypic features, such as the expression
of CD30 and CD15 [23, 38, 103, 107, 129]. In 1994, the
ILSG included in the REAL classification a provisional entity
called “lymphocyte rich common Hodgkin’s disease”, which
was thought to have a diﬀuse growth pattern in most
instances (Table 1) [16]. Following two workshops held by
the European Association for Haematopathology in 1994 and
the European lymphoma task force in 1995, the existence of
LR- cHL has been accepted and expanded by the recognition
of two subtypes of the tumor, nodular and diﬀuse, which
should be diﬀerentiated from LP-HL and TCRBCL (Table 1)
[1, 17–20, 22, 130–133].
On morphological grounds [19], most LR- cHL cases
are characterized by a nodular background, with admixed
histiocytes and absent neutrophils and eosinophils closely
resembling nodular LP-HL, particularly at low power. Fur-
thermore, a varying proportion of the neoplastic cells can
exhibit features of popcorn elements. However, in contrast to
LP-HL, many lymphomatous cells have the cytomorpholog-
ical features of classic H&RS cells, and the nodular structures
frequently show small germinal centres at their periphery.
Focal areas of sclerosis can sometimes be seen.
At phenotypic analysis [19], the neoplastic cells usually
express CD30 and CD15. CD20 and CD79a positivity is
found in 32.5% and 8.7% of cases, respectively—figures that
are much lower than those observed in LP-HL. In addition,
there is a complete absence of J chain in all instances and
a weak expression of EMA in only a few cases. About 50%
of the examples of LR- cHL harbour EBV positive H&RS
cells. The reactive component consists of abundant mantle
B cells, with surface IgD and IgM expression, and variable
amounts of CD3+ T cells, which produce rosettes around
neoplastic elements, but they seldom express CD57. CD21
immunostaining reveals a loose, ill defined meshwork of
FDCs, which becomes much denser and sharper around the
small residual germinal centres, when present.
On clinical ground, patients with LR- cHL diﬀer from
those with NS- cHL or MC- cHL; they are usually older
than 50 and display a higher incidence of stages I–II and
a subdiafragmatic location. In contrast, they rarely have
bulky disease, B-cell symptoms, or mediastinal or extranodal
involvement [19, 134]. Thus, the clinical profile of LR- cHL is
closer to that of LP-HL although it has a lower frequency of
stages I-II and splenic infiltration is more common. When
compared with other types of cHL, LR-cHL gives rise to
more frequent late relapses although these do not behave
aggressively.
Owing to its peculiar clinicopathological features, LR-
cHL has been quoted as an accepted entity in the recently
developed WHO scheme [1, 9, 17–20].
3.10. Unclassifiable HL. In cases with lymph node partial
involvement, small amounts of tissue available, or extranodal
location, the classification of HL can be diﬃcult or even
impossible. In the past, these problematical cases were
usually included in the MC subtype. Because it is useful to
keep the subtypes of HL as homogeneous as possible for
prospective clinicopathological studies, both the REAL clas-
sification and the WHO scheme list cases with ambiguous
features or insuﬃcient bioptic material as HL unclassified.
3.11. Lymphomas with Intermediate Features
between cHL and DLBCL. This new distinct entity (pre-
viously called grey zone lymphoma) has been introduced
in the 4th edition of WHO classification of Tumours
of Haematopoietic and Lymphoid Tissues and includes B
lineage lymphoma with overlapping clinical, morphological,
and immunophenotypic features between cHL and DLBCL,
in particular primary mediastinal large B-cell lymphoma
(PMBL) [135]. The clinical onset is often represented by
a large anterior mediastinal mass which may involve the
lung and may be associated to a vena cava syndrome. The
disease is frequently more aggressive than cHL and PMBL.
Morphologically the neoplastic population is pleomorphic
with a sheet-like growth pattern; areas richer in lacunar and
Hodgkin cells and others more similar to a DLBCL are
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frequently observed. Similarly to DLBCL, the immunophe-
notype is characterized by the expression of CD45, of B-cell
antigens CD20 and CD79a, and transcription factors PAX5,
BOB1, and OCT2 but is also associated to cHL markers
CD30 and CD15 positivity [135]. Sometimes a neoplasia
resembling morphologically a PMBL but negative for CD20
can occur; in these instances, a diagnosis of lymphoma
with intermediate features between cHL and DLBCL can
be made if supported by CD15 and/or EBV positivity
[135].
Of note, some of EBV-positive DLBCL of the elderly are
pathologically similar to HL and should be considered in the
diﬀerential diagnosis of EBV-positive HL [136, 137].
4. Extranodal Involvement by HL
Although the onset is typically nodal, HL can secondarily
aﬀect extranodal organs and tissues. The criteria for the
diagnosis of HL at extranodal sites vary greatly depending
on the clinical history and the type of tissue involved. In
fact, in needle biopsies taken from the bone marrow and
liver during staging procedures, the diagnosis of HL can
confidently be made according to “minimal criteria”; that
is, by the detection of HC in the appropriate cellular milieu
[127]. In contrast, the diagnosis of HL at other extranodal
sites needs the recognition of typical “diagnostic” cells and
appropriate phenotypic markers, especially in patients with
no previous history of HL.
Expert Opinion. Thanks to the results provided by immu-
nophenotypic and molecular studies, Hodgkin’s lymphoma
(HL) is now basically considered to be a germinal centre-
related B-cell lymphoma. Notably, significant diﬀerences
exist between LP-HL and cHL (which includes the NS,
MC, LR, and LD subtypes) in terms of natural history, the
relation to Epstein-Barr virus, cell morphology, phenotype,
molecular characteristics, and clinical behavior. Further,
although the borders between HL and ALCL have recently
become sharp, the diﬀerential diagnosis between LP-HL and
T-cell rich B-cell lymphoma remains at times problematical.
Interestingly, the lack of immunoglobulin (Ig) production,
which is characteristic of cHL, is more often the result of
defective expression of transcription factors, such as OCT-
2, BOB.1, and PU.1, although at times it is caused by the
occurrence of crippling IGH gene mutations. Finally, the
search for morphological, phenotypic, and/or kinetic factors
that may herald a poor response to conventional treatments
is felt necessary, aiming to design and to apply more eﬀective
ad hoc strategies in selected cases. In particular, strategies
aimed at interfering with the crosstalk between RS cells
and their cellular accomplices should take into account that
the same cellular subset may play diﬀerent, even opposite,
functions according to the signals it senses. This suggests
a note of caution regarding the adoption of therapies able
to alter the composition of the HL-associated microen-
vironment, such as monoclonal-antibody-based humoral
immunotherapies (e.g., Rituximab) or immunomodulatory
drugs (e.g., lenalidomide) [138, 139]. On the other hand,
other target therapies such as anti-CD30 antibodies and
anti-NFkB drugs may provide a significant benefit in the
limited but still significant fraction of chemoresistant HL
patients.
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